CRISPR and Cancer

Researchers at ETH Zürich have introduced a combined base and prime editing approach to explore the mutational landscape of the epithelial growth...

In Vivo T-Cell Editing in Lymph Nodes Effectively...

CMN Briefs

Nov. 26, 2024

A new method for directly editing T-cells in lymph nodes using CRISPR-Cas9 aims to enhance immune checkpoint blockade (ICB) cancer therapies. The...

In Vivo T-Cell Editing in Lymph Nodes Effectively...

CMN Briefs

Nov. 26, 2024

A new method for directly editing T-cells in lymph nodes using CRISPR-Cas9 aims to enhance immune checkpoint blockade (ICB) cancer therapies. The...

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

FDA Clears First CRISPR-Cas13 RNA-Editing Trial...

CMN Clinical

Nov. 6, 2024

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

CRISPR Plus Drug Treatment Makes Neuroblastoma...

CMN Briefs

Oct. 24, 2024

Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.

The Latest Updates From the Gene-Editing Clinical...

CMN Clinical

Oct. 9, 2024

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...

Gene editing boosts CAR-NK efficacy against...

CMN Briefs

Oct. 1, 2024

German scientists have presented a dual modification strategy that combines CRISPR-Cas9 and CAR technology to enhance the efficacy of natural killer...